-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Andexanet Should Be Used to Reverse Xai Anticoagulants

Program: Spotlight Sessions
Session: Debate: PCC or Andexanet alfa for Managing Bleeding in Patients on Oral Xa Inhibitors?
Hematology Disease Topics & Pathways:
Diseases, Myeloid Malignancies
Sunday, December 10, 2023, 4:30 PM-5:45 PM

Deborah Siegal, MD, MSc

Department of Medicine, University of Ottawa, Ottawa, ON, Canada

Disclosures: Siegal: Roche: Honoraria, Other: paid indirectly to my institution; Servier: Honoraria, Other: paid indirectly to my institution; BMS-Pfizer: Honoraria, Other: paid indirectly to my institution; Astra Zeneca: Honoraria, Other: paid indirectly to my institution.

OffLabel Disclosure: PCC is used off-label for DOAC-related bleeding

See more of: Debate: PCC or Andexanet alfa for Managing Bleeding in Patients on Oral Xa Inhibitors?
See more of: Spotlight Sessions
<< Previous Presentation | Next Presentation